LivaNova PLC Q2 2026 Earnings Call Summary
LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.
How this was made
The 30-second read
Why it matters
Traders can update positioning around 2026 growth and EPS expectations, while also reassessing cash-flow trajectory and the regulatory timeline for the next-generation OSA system.
Market read
The combination of raised revenue/EPS guidance and lowered free-cash-flow guidance, plus a PMA timing shift, is likely to drive re-rating around growth quality and cash conversion for 2026.
What to watch
The one-time $6 million tariff benefit boosts Q2 gross margin but will not recur, and the guidance assumes consumables market share gains tied to production lines coming online in 2H 2026.
Background
The piece summarizes LivaNova’s Q2 2026 earnings call, focusing on segment drivers, updated 2026 guidance, operational updates, and select clinical/regulatory discussion.
Ticker impact
LivaNova raised 2026 revenue growth guidance to 8% to 9% and adjusted EPS to $4.30 to $4.40, plus changed FCF and PMA timelines.
Likely near-term volatility as investors weigh higher growth and EPS against lower adjusted free cash flow and regulatory-timeline risk.
The article discloses multiple forward-looking datapoints (revenue/EPS/FCF guidance, OSA PMA timing shift, and a new Thermo Fisher oxygenator-component supply agreement) that can reprice both growth and cash-flow expectations, but it is a call summary rather than a fresh filing or print.
Market effects
Cardiopulmonary and epilepsy medtech peers may see read-across on reimbursement-driven demand and supply-chain normalization via long-term component agreements.
No explicit regional macro drivers beyond “all geographic regions,” so limited incremental regional read-through.
Thermo Fisher supply agreement and manufacturing capacity expansion could influence broader oxygenator component supply expectations, but the article is company-specific.
Counterpoint
The raised growth and EPS guidance may be partially offset by higher capex and a delayed OSA PMA supplement window, which could pressure valuation if investors prioritize cash conversion and regulatory timing.
Key entities
- companyLivaNova PLC
Raised 2026 revenue and adjusted EPS guidance, lowered adjusted free cash flow guidance, and discussed supply-chain and regulatory timing updates.
- counterpartyThermo Fisher Scientific
Entered a long-term agreement for a critical oxygenator component to remove supply constraints.
- product/therapyCORE-VNS
Real-world evidence discussed as strengthening clinician confidence and earlier adoption of VNS Therapy.
- product/regulatoryOSA system (next-generation)
PMA supplement submission timeline adjusted to between H2 2026 and H1 2027 due to design verification.
- clinical programRECOVER trial
36-month data submitted to a preprint and peer-reviewed journal; CMS requires formal publication for coverage decisions.
